Clinical trial
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With…
NCT00003880 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00003880 |
|---|---|
| Title | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer |
| Official title | A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Biological, Drug |
| Interventions | recombinant adenovirus-p53 SCH-58500, carboplatin, paclitaxel |
| Enrollment | 132 |
| Start date | Feb 1, 1999 |
| Primary completion | Aug 1, 2001 |
| Completion | Aug 1, 2001 |
| First posted | Apr 23, 2004 |
| Last update posted | Apr 16, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: